Immunotherapy and its impact on overall survival in patients with recurrent endometrial cancer-Recording

Video Transcription

Video Summary

Matt Powell, the chair of the NRG Corpus Committee, discusses the Ruby trial's impact on metastatic endometrial cancer treatment in a conversation with Wendell Nauman. The trial combined immunotherapy with standard chemotherapy, showing significant survival benefits. Powell emphasizes the importance of combining chemotherapy with immunotherapy, especially for MMR-deficient patients. He also addresses subgroup analysis and potential future directions in utilizing immunotherapy, highlighting the need for ongoing research and personalized care. Overall, the discussion underscores the promising advancements in endometrial cancer treatment and the vital role of clinical trials in driving progress in the field.

Keywords

Matt Powell

NRG Corpus Committee

Ruby trial

metastatic endometrial cancer treatment

immunotherapy